How do clinicians integrate oral octreotide into their treatment plan for acromegaly?
Lancet Diabetes Endocrinol
.
2022 Feb;10(2):86-87.
doi: 10.1016/S2213-8587(21)00319-3.
Epub 2021 Dec 22.
Author
Maya B Lodish
1
Affiliation
1
Department of Pediatric Endocrinology, University of California, San Francisco, CA 94143, USA. Electronic address: maya.lodish@ucsf.edu.
PMID:
34953532
DOI:
10.1016/S2213-8587(21)00319-3
No abstract available
Publication types
Comment
MeSH terms
Acromegaly* / drug therapy
Humans
Octreotide* / therapeutic use
Somatostatin
Substances
Somatostatin
Octreotide